126 related articles for article (PubMed ID: 9065804)
1. In vitro mutagenicity of the plasmacytomagenic agent pristane (2,6,10,14-tetramethylpentadecane).
Felix K; Potter M; Bornkamm GW; Janz S
Cancer Lett; 1997 Feb; 113(1-2):71-6. PubMed ID: 9065804
[TBL] [Abstract][Full Text] [Related]
2. Disposition of the plasmacytomagenic alkane pristane (2,6,10,14-tetramethylpentadecane) in mice.
Janz S; Shacter E
Cancer Biochem Biophys; 1995 Jun; 15(1):25-34. PubMed ID: 8536217
[TBL] [Abstract][Full Text] [Related]
3. Elevated mutant frequencies in lymphoid tissues persist throughout plasmacytoma development in BALB/c.lambdaLIZ mice.
Felix K; Kelliher KA; Bornkamm GW; Janz S
Cancer Res; 1999 Aug; 59(15):3621-6. PubMed ID: 10446972
[TBL] [Abstract][Full Text] [Related]
4. The fluidity of DOPC bilayers and membrane fractions prepared from murine plasmacytoma cells is unchanged after incorporation of pristane (2,6,10,14-tetramethylpentadecane) as assessed by fluorescence polarization analysis.
Janz S; Krumbiegel M; Gawrisch K
Cancer Biochem Biophys; 1992 Nov; 13(2):85-92. PubMed ID: 1343851
[TBL] [Abstract][Full Text] [Related]
5. Tetravinyl-tetramethylcyclo-tetrasiloxane (tetravinyl D4) is a mutagen in Rat2lambda lacI fibroblasts.
Felix K; Lin S; Bornkamm GW; Janz S
Carcinogenesis; 1998 Feb; 19(2):315-20. PubMed ID: 9498283
[TBL] [Abstract][Full Text] [Related]
6. Genotoxicity assessment of the plasmacytomagenic agent pristane (2.6.10.14-tetramethylpentadecane) and four related alkanes by the SOS chromotest.
Janz S; Huttunen T; Herzschuh R; Storch H
Arch Geschwulstforsch; 1988; 58(2):73-8. PubMed ID: 3288166
[TBL] [Abstract][Full Text] [Related]
7. A new method for delivering alkanes to mammalian cells: preparation and preliminary characterization of an inclusion complex between beta-cyclodextrin and pristane (2,6,10,14-tetramethylpentadecane).
Janz S; Shacter E
Toxicology; 1991; 69(3):301-15. PubMed ID: 1949053
[TBL] [Abstract][Full Text] [Related]
8. 1,3-butadiene: cancer, mutations, and adducts. Part II: Roles of two metabolites of 1,3-butadiene in mediating its in vivo genotoxicity.
Recio L; Saranko CJ; Steen AM
Res Rep Health Eff Inst; 2000 Mar; (92):49-87; discussion 141-9. PubMed ID: 10925839
[TBL] [Abstract][Full Text] [Related]
9. The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane.
Avcu F; Ural AU; Yilmaz MI; Ozcan A; Ide T; Kurt B; Yalcin A
Eur J Haematol; 2005 Jun; 74(6):496-500. PubMed ID: 15876253
[TBL] [Abstract][Full Text] [Related]
10. Elevated mutant frequencies in gene lacI in splenic lipopolysaccharide blasts after exposure to activated phagocytes in vitro.
Felix K; Lin S; Janz S
Eur J Immunol; 1997 Sep; 27(9):2160-4. PubMed ID: 9341754
[TBL] [Abstract][Full Text] [Related]
11. Fusion between enveloped viruses and erythrocyte membranes is induced by the isoprenoid alkane pristane (2,6,10,14-tetramethylpentadecane).
Janz S; Shacter E; Herrmann A
Cancer Biochem Biophys; 1994 Apr; 14(1):1-14. PubMed ID: 7796384
[TBL] [Abstract][Full Text] [Related]
12. Translocation and activation of protein kinase C by the plasma cell tumor-promoting alkane pristane.
Janz S; Gawrisch K; Lester DS
Cancer Res; 1995 Feb; 55(3):518-24. PubMed ID: 7834620
[TBL] [Abstract][Full Text] [Related]
13. Differential in vivo mutagenicity of the carcinogen/non-carcinogen pair 2,4- and 2,6-diaminotoluene.
Hayward JJ; Shane BS; Tindall KR; Cunningham ML
Carcinogenesis; 1995 Oct; 16(10):2429-33. PubMed ID: 7586147
[TBL] [Abstract][Full Text] [Related]
14. Induction of B cell autoimmunity by pristane.
Richards HB; Satoh M; Shaheen VM; Yoshida H; Reeves WH
Curr Top Microbiol Immunol; 1999; 246():387-92; discussion 393. PubMed ID: 10396079
[No Abstract] [Full Text] [Related]
15. Perturbation of B cell genesis in the bone marrow of pristane-treated mice. Implications for plasmacytoma induction.
Rico-Vargas SA; Potter M; Osmond DG
J Immunol; 1995 Mar; 154(5):2082-91. PubMed ID: 7868885
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of pristane-induced peritoneal plasmacytoma formation.
Potter M; Kutkat L
Curr Top Microbiol Immunol; 1999; 246():351-61; discussion 361-2. PubMed ID: 10396075
[TBL] [Abstract][Full Text] [Related]
17. Pristane induces an indomethacin inhibitable inflammatory influx of CD4+ T cells and IFN-gamma production in plasmacytoma-susceptible BALB/cAnPt mice.
McDonald AH; Degrassi A
Cell Immunol; 1993 Jan; 146(1):157-70. PubMed ID: 8425224
[TBL] [Abstract][Full Text] [Related]
18. Peritoneal plasmacytomagenesis in mice: comparison of different pristane dose regimens.
Potter M; Wax JS
J Natl Cancer Inst; 1983 Aug; 71(2):391-5. PubMed ID: 6576197
[TBL] [Abstract][Full Text] [Related]
19. Induction of plasma cell tumours with 2,6,10,14-tetramethylpentadecane (pristane) and paraffin oil (paraffinum perliquidum) in BALB/c mice simultaneously exposed to sustained antigenic stimulation with bovine serum albumin (BSA).
Janz S; Püschel W; Raabe F; Storch H
Arch Geschwulstforsch; 1987; 57(1):25-30. PubMed ID: 3566462
[TBL] [Abstract][Full Text] [Related]
20. Pristane retards clearance of particulate materials from the peritoneal cavity of laboratory mice.
Moore JM; Rajan TV
J Immunol Methods; 1994 Aug; 173(2):273-8. PubMed ID: 7519224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
